Dendreon Corporation Cancer Drug, Provenge Faces U.S. Review Tied to Its Sole Product
Bloomberg -- Dendreon Corp. is relying on a decision by Medicare to help generate $1.75 billion a year for the prostate cancer drug Provenge, the company’s only product.